Townsville Bulletin



AN AUSTRALIAN biotech company is the first in the world to develop a potential nanocellul­ar Covid-19 vaccine that’s expected to be more efficient against mutant strains and better suited for patients with compromise­d immune systems.

The drug developed by Sydney-based company EnGeneic has shown 95 per cent efficacy in its preclinica­l animal studies.

The technology used for the drug was initially developed as a breakthrou­gh cancer treatment but has been adjusted to work as a vaccine.

Phase 1 clinical trials in healthy humans have begun at Melbourne’s St Vincent’s Hospital. Another trial is due to establishe­d in Sydney.

According to the company, the vaccine can be kept at room temperatur­e, has a shelf life of more than three years and doesn’t have added stabiliser­s or chemicals.

Newspapers in English

Newspapers from Australia